Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aditxt, Inc. - Common Stock (NQ:ADTX)

1.020 -0.010 (-0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 122,547
Open 1.030
Bid (Size) 1.000 (48)
Ask (Size) 1.030 (1)
Prev. Close 1.030
Today's Range 1.000 - 1.050
52wk Range 0.8100 - 11,700.00
Shares Outstanding 44,714,213
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Portfolio Company CEO Honored at 2025 STIMULATE Conference
Via Investor Brand Network

Performance

YTD
-97.9%
-97.9%
1 Month
-15.7%
-15.7%
3 Month
-41.7%
-41.7%
6 Month
-96.3%
-96.3%
1 Year
-100.0%
-100.0%

More News

Read More
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Spartan Capital as Lead Underwriter for Planned IPO
Via Investor Brand Network
Topics Initial Public Offering
Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Invited to Submit Full Proposal for DoD-Funded Ovarian Cancer Diagnostic Study
Via Investor Brand Network
Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
From Aditxt, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host July 22 Livestream on Autoimmune Therapeutics Subsidiary Adimune
Via Investor Brand Network
Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET
From Aditxt, Inc.
Via Business Wire
Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization
From Aditxt, Inc.
Via Business Wire
Unusual volume stocks in Wednesday's session
Via Chartmill
Which stocks have an unusual volume on Thursday?
Via Chartmill
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) CEO to Present at Wall Street Reporter’s NEXT SUPER STOCK Event June 26
Via Investor Brand Network
Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
From Aditxt, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors
From Aditxt, Inc.
Via Business Wire
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics
Via Investor Brand Network
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
Via Investor Brand Network
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
From Aditxt, Inc.
Via Business Wire
KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
Via Business Wire

Frequently Asked Questions

Is Aditxt, Inc. - Common Stock publicly traded?
Yes, Aditxt, Inc. - Common Stock is publicly traded.
What exchange does Aditxt, Inc. - Common Stock trade on?
Aditxt, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aditxt, Inc. - Common Stock?
The ticker symbol for Aditxt, Inc. - Common Stock is ADTX on the Nasdaq Stock Market
What is the current price of Aditxt, Inc. - Common Stock?
The current price of Aditxt, Inc. - Common Stock is 1.020
When was Aditxt, Inc. - Common Stock last traded?
The last trade of Aditxt, Inc. - Common Stock was at 08/15/25 04:00 PM ET
What is the market capitalization of Aditxt, Inc. - Common Stock?
The market capitalization of Aditxt, Inc. - Common Stock is 45.61M
How many shares of Aditxt, Inc. - Common Stock are outstanding?
Aditxt, Inc. - Common Stock has 46M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.